Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

Exclusion Criteria

• •Patients are not receiving chemotherapy
• •Patients already included in an epoetin zeta trial
• •Patients presenting with a contraindication to epoetin zeta
• •Patients presenting with hypersensitivity to the active principle or any of the excipients
• •Patient with erythroblastopenia or acquired pure red cell aplasia (APRCA)
• •Patient with uncontrollable arterial hypertension
• •Patients who cannot receive adequate prophylaxis by antithrombotic agents